Gujarat Themis Biosyn Share Price Today

Gujarat Themis Biosyn AGM rejects promoter loan proposal; 8 other resolutions pass

Gujarat Themis Biosyn Ltd passed 8 of 9 resolutions at its 45th AGM held on September 30, 2026. Resolution 7 seeking approval for loans from promoters was rejected with 59.86% votes against. Public institutions cast 12.63 million votes against the promoter loan proposal. Preferential issue of equity shares and amendment to Articles of Association were approved.

Gujarat Themis Biosyn fixes Sept 23 record date for FY26 final dividend

Record date for final dividend is September 23, 2026. Payout relates to financial year ended March 31, 2026. Approval required at AGM on September 30, 2026. Disclosure made under SEBI Listing Regulations Regulation 42.

Gujarat Themis Biosyn completes MicroBiopharm Japan acquisition for JPY 21.5 billion

Gujarat Themis Biosyn completed the acquisition of MicroBiopharm Japan for JPY 21.5 billion on September 18, 2026. The deal is funded via ₹475 crore capital contribution and ₹745 crore loan to its Japanese subsidiary. Earlier issuance of ₹585 crore in secured NCDs supports the transaction and general corporate purposes. Target generates JPY 9.5 billion revenue with 40% from outside Japan and strong FDA/PMDA compliance.

Gujarat Themis Biosyn seeks AGM approval for Articles of Association amendment

Gujarat Themis Biosyn issued an addendum for its 45th AGM on September 30, 2026. Seeks approval to amend Article 119 to broaden the definition of Financial Institutions. Proposes allowing lenders to appoint board observers instead of nominee directors. Aims to provide flexibility in borrowing from diverse lending entities.

Gujarat Themis closes ₹75 crore QIP at ₹354; promoter stake diluted

Gujarat Themis Biosyn closed its QIP raising ₹75 crore at ₹354 per share. Promoters disclosed passive dilution of stake to 59.33% post-allotment. Quant Small Cap Fund emerged as largest single allottee with 25.67% stake. Paid-up equity capital increased to ₹13.01 crore from ₹10.89 crore.

Gujarat Themis Biosyn approves ₹335 crore preferential share allotment

Gujarat Themis Biosyn board approves preferential allotment of 82.11 lakh equity shares. Issue priced at ₹408 per share, raising up to ₹335 crore in total. Promoter group entity Pharmaceutical Business Group (India) Ltd takes largest stake of ₹250 crore. Four non-promoter investors include Special Situation India Fund and ISAF III Onshore Fund. Transaction requires shareholder and stock exchange approvals before finalisation.